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p53, a transcription factor expressed in
all cells, is the most frequently genetical-
ly altered tumor suppressor in human
cancers (Vogelstein et al., 2000). In
tumors where p53 itself remains intact,
p53 function can be inactivated by genet-
ic alterations of other genes in the p53
pathway, including deletion of the alter-
native reading frame gene (Arf) (Quelle
et al., 1995) or overexpression of Mdm2
(Juven-Gershon and Oren, 1999). p19Arf
in the mouse (p14ARF in humans), like
p53, is a potent tumor suppressor that
positively regulates p53 transcriptional
activity by binding to and sequestering
Mdm2. Mdm2, a transcriptional target of
p53, is an E3 ubiquitin ligase that nega-
tively regulates p53 transcriptional activi-
ty by binding to it and catalyzing its
ubiquitination, thereby targeting it for
degradation by the proteasome (Juven-
Gershon and Oren, 1999). Mdm2 is fre-
quently found overexpressed in human
tumors, leading to the rapid degradation
of p53, which is equivalent to loss of p53
function.
p53’s transcriptional program pro-
tects cells against the destructive effects
of DNA-damaging agents, including γ
irradiation or chemotherapeutic drugs, or
of oncogenic stresses from hyperprolifer-
ative signals induced by activated proto-
oncogenes, such as Myc or Ras. p53
suppresses tumor growth by halting cell
proliferation, a process called premature
senescence, or by triggering a cell sui-
cide program, also called apoptosis.
However, the genes whose expression is
regulated by p53 which control each of
these two outcomes have not been com-
pletely mapped.
Apoptosis, or programmed cell death,
is an active process activated in response
to DNA damage. Mutations in the
apoptotic pathway, including p53, lead to
tumorigenesis and resistance to chemo-
therapeutic drugs in cell lines and in vivo
(Johnstone et al., 2002). Senescence was
originally defined as a mechanism that
limits the lifespan of fibroblasts by a finite
number of divisions. Replicative senes-
cence, the so-called “Hayflick limit,” is
linked to the progressive shortening of
telomeres leading to the physiological
process of aging. Mechanisms that pro-
tect telomere ends play a role in immortal-
ization and carcinogenesis (Hayflick and
Moorhead, 1961). However, a telomere-
independent, p53-dependent type of
senescence, also called premature
senescence, can be triggered by acute
cellular stresses that include activated
oncogenes, reactive oxygen systems,
anticancer agents, and γ irradiation
(Serrano et al., 1997). One of the stress-
induced forms of senescence, coined
“culture shock” by Sherr and Depinho,
also involves the induction of the tumor
suppressors p16Ink4a and p19Arf as well as
p53, but seems to be due mainly to cul-
ture conditions that may have no signifi-
cance in vivo (Sherr and DePinho, 2000).
Therefore, apoptosis and senes-
cence both constitute failsafe mecha-
nisms that force cells to irreversibly exit
the cell cycle, and by doing so, prevent
cells from unscheduled growth and can-
cer. p53 and p19Arf have both been impli-
cated in the regulation and control of
replicative and premature senescence.
Mouse embryo fibroblasts (MEFs) from
p53-deficient and Arf null mice are
immortal and fail to enter premature
senescence, and mice lacking either of
these two tumor suppressors develop a
variety of tumors that are refractory to
therapy (Sherr and McCormick, 2002).
Similarly, human tumors lacking p53
function are resistant to chemotherapy,
stimulating a number of groups to
attempt to restore p53 activity in tumor
cells that harbor a defective p53 protein,
to sensitize them to DNA damaging
agents. Small molecules that reactivate
mutant p53 by restoring its DNA binding
activity and transcriptional activity were
reported to provide antitumor activity in
vivo (Bykov et al., 2002). Tyner and col-
laborators constitutively expressed p53
in mice and found that p53 restoration
indeed decreased the incidence of spon-
taneous tumors (Tyner et al., 2002)
(Table 1). However, unexpectedly, this
beneficial effect came at a big price: the
induction of premature aging. These
results supported the idea that constitu-
tively active p53 was ultimately responsi-
ble for premature aging (Ferbeyre and
Lowe, 2002).
A research group from the Spanish
National Center of Biotechnology in
Madrid, led by Dr. Manuel Serrano, now
finds that excess levels of the wild-type
tumor suppressor p53 protect mice
against cancer and aging (Garcia-Cao et
al., 2002). These results are surprising
and exciting because they offer for the
first time a ray of hope that increased lev-
els of p53, expressed from its own
endogenous promoter, may protect us
against cancer without the undesirable
side effects of aging. Garcia-Cao and
collaborators report the generation of
novel transgenic mice, called “super
p53.” The super p53 mice express wild-
type endogenous p53, and also carry
one or two extra copies of a normal p53
p53: Regular or super?
Increased p53 expression under the endogenous promoter protects “super p53” mice from tumorigenesis without the
undesirable effects of premature aging.
Table 1. p53 levels dictate tumorigenesis, aging, or apoptosis
Incidence of 
Genotypes p53 status tumor formation Premature aging Apoptosis
Wild-type + + − +
Null − ++++ − −
Transgenic ++++ − ++ ++
(Tyner et al, 2002) (under 
heterologous 
promoter)
Transgenic ++ − − ++
(Garcia-Cao (under
et al., 2002) endogenous 
promoter)
(−), cells lacking p53, absence of premature aging, tumor formation or apoptosis; (+), normal p53 lev-
els from endogenous p53 gene, low incidence of tumor formation, and apoptosis; (++), one or two
extra copies of p53 under the control of endogenous promoter, premature aging, and apoptosis;
(++++), high levels of p53 expression or increased incidence of tumor formation.
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gene, inserted as transgenes in the form
of large genomic fragments of 130 to 175
kilobases. Because the additional p53
gene is expressed from its own promot-
er, the transgenically expressed p53
seems to be regulated in the same fash-
ion as endogenous p53. This contrasts
with the previous expression of an acti-
vated mutant form of p53 from a heterol-
ogous promoter reported by Tyner and
collaborators. The super p53 mice were,
as expected, more sensitive to DNA
damage, as higher levels of p53 induce
increased apoptosis and senescence,
and were significantly protected from
chemically induced cancers when com-
pared to normal mice that carry only two
alleles of a wild-type p53 gene. However,
contrary to the initial prediction from the
data reported by Tyner and collabora-
tors, these super p53 mice did not show
any signs of aging (Table 1). One of the
reasons for the absence of undesirable
premature aging effects in the super p53
mice may be that increased levels of the
wild-type p53 were regulated from p53’s
own endogenous promoter. In fact, the
same large genomic fragment (or trans-
gene) was also found to restore normal
p53 functions when introduced into mice
lacking p53, suggesting that the p53
expressed from the transgene was
appropriately regulated, and sufficient
levels of p53 protein were available to
compensate for the lack of endogenous
p53. Another reason for the success of
super p53 mice in protection from
tumorigenesis may be that an increased
copy number of p53 may decrease the
probability for stochastic mutations. Cells
would therefore commit suicide in
response to DNA damage, reducing the
emergence of tumor cells.
Regardless of the reason for their
potential success, the super p53 mice
provide hope that protection of cells
against cancer might be possible by
introducing large fragments of DNA con-
taining a tumor suppressor gene in stem
cells before transplantation in patients.
Even though there is still a significant
gap between our ability to prevent can-
cer in mice and in humans, this report
provides an alternative to the restoration
of lost or defective protein functions by
retroviral gene transfer. Although in
many cases, “less is more,” when talking
about p53, more appears to be better.
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